Trevena Inc. (NASDAQ:TRVN) CEO Maxine Gowen acquired 12,500 shares of the business’s stock in a transaction dated Monday, November 7th. The stock was acquired at an average price of $4.10 per share, with a total value of $51,250.00. Following the completion of the transaction, the chief executive officer now directly owns 16,500 shares of the company’s stock, valued at $67,650. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Shares of Trevena Inc. (NASDAQ:TRVN) opened at 6.09 on Monday. The firm’s market capitalization is $318.71 million. Trevena Inc. has a 12-month low of $3.76 and a 12-month high of $13.02. The stock has a 50 day moving average price of $5.80 and a 200 day moving average price of $6.65.

Trevena (NASDAQ:TRVN) last announced its quarterly earnings data on Thursday, November 3rd. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.40) by $0.17. Trevena had a negative net margin of 841.00% and a negative return on equity of 66.50%. Analysts predict that Trevena Inc. will post ($1.91) EPS for the current fiscal year.

Institutional investors have recently bought and sold shares of the stock. Wellington Management Group LLP increased its stake in Trevena by 47.0% in the first quarter. Wellington Management Group LLP now owns 5,714,773 shares of the biopharmaceutical company’s stock worth $47,262,000 after buying an additional 1,827,970 shares during the period. National Planning Corp increased its stake in shares of Trevena by 21.9% in the first quarter. National Planning Corp now owns 19,452 shares of the biopharmaceutical company’s stock worth $151,000 after buying an additional 3,500 shares during the period. Vivo Capital LLC bought a new stake in shares of Trevena during the first quarter worth approximately $9,924,000. First Manhattan Co. bought a new stake in shares of Trevena during the second quarter worth approximately $729,000. Finally, Alps Advisors Inc. increased its stake in shares of Trevena by 28.3% in the second quarter. Alps Advisors Inc. now owns 73,294 shares of the biopharmaceutical company’s stock worth $462,000 after buying an additional 16,169 shares during the period. 75.52% of the stock is owned by institutional investors.

TRVN has been the subject of several research reports. Brean Capital set a $14.00 price target on Trevena and gave the stock a “buy” rating in a research report on Thursday, September 15th. Zacks Investment Research lowered Trevena from a “hold” rating to a “sell” rating in a research note on Thursday, October 6th. Jefferies Group reaffirmed a “buy” rating on shares of Trevena in a research note on Friday, August 5th. Wedbush reaffirmed an “outperform” rating and issued a $16.00 price target on shares of Trevena in a research note on Thursday, November 3rd. Finally, Cowen and Company reaffirmed a “buy” rating and issued a $13.00 price target on shares of Trevena in a research note on Friday, August 5th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $14.30.

Trevena Company Profile

Trevena Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and intends to commercialize therapeutics that use an approach to target G protein coupled receptors (GPCRs). Using its product platform, the Company has identified and advanced three differentiated product candidates: Oliceridine (TRV130), TRV027 and TRV250.

5 Day Chart for NASDAQ:TRVN

Receive News & Stock Ratings for Trevena Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena Inc. and related stocks with our FREE daily email newsletter.